Compare DEI & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DEI | VCEL |
|---|---|---|
| Founded | 1971 | 1989 |
| Country | United States | United States |
| Employees | 778 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2006 | 1996 |
| Metric | DEI | VCEL |
|---|---|---|
| Price | $9.35 | $30.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $13.19 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 2.3M | 631.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | 0.09 | ★ 0.32 |
| Revenue | ★ $1,003,982,000.00 | $276,259,000.00 |
| Revenue This Year | $2.29 | $19.10 |
| Revenue Next Year | $2.04 | $17.95 |
| P/E Ratio | $102.11 | ★ $91.69 |
| Revenue Growth | 1.77 | ★ 16.45 |
| 52 Week Low | $9.12 | $28.95 |
| 52 Week High | $16.94 | $45.97 |
| Indicator | DEI | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 36.78 |
| Support Level | N/A | $29.59 |
| Resistance Level | $10.18 | $38.48 |
| Average True Range (ATR) | 0.31 | 1.54 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 19.81 | 26.90 |
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.